RT Journal Article
T1 Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
A1 Casasnovas, Rene-Olivier
A1 Follows, George
A1 Zijlstra, Josee M
A1 Vermaat, Joost S P
A1 Kalakonda, Nagesh
A1 Choquet, Sylvain
A1 Neste, Eric Van Den
A1 Hill, Brian
A1 Thieblemont, Catherine
A1 Cavallo, Federica
A1 la Cruz, Fatima De
A1 Kuruvilla, John
A1 Hamad, Nada
A1 Jaeger, Ulrich
A1 Caimi, Paolo F
A1 Gurion, Ronit
A1 Warzocha, Krzysztof
A1 Bakhshi, Sameer
A1 Sancho, Juan-Manuel
A1 Schuster, Michael
A1 Egyed, Miklos
A1 Offner, Fritz
A1 Vassilakopoulos, Theodoros P
A1 Samal, Priyanka
A1 Ku, Matthew
A1 Ma, Xiwen
A1 Chamoun, Kamal
A1 Shah, Jatin
A1 Canales, Miguel
A1 Maerevoet, Marie
A1 Shacham, Sharon
A1 Kauffman, Michael G
A1 Goy, Andre
K1 DLBCL subtypes
K1 De novo and transformed DLBCL
K1 Relapsed/refractory DLBCL
K1 Salvage therapy
K1 Treatment response
K1 XPO1
AB The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor. Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response rate (ORR), overall survival (OS), duration of treatment response, progression-free survival, and adverse events rate. ORR in the entire cohort was 29.1%, and similar in patients with germinal center (GCB) versus non-GCB DLBCL (31.7% vs. 24.2%, P = 0.45); transformed DLBCL showed a trend towards higher ORR than de novo DLBCL: 38.7% vs. 26.2% (P = 0.23). Despite similar prior treatment regimens and baseline characteristics, patients with DLBCL and normal C-MYC/BCL-2 protein expression levels had a significantly higher ORR (46.2% vs.14.8%, P = 0.012) and significantly longer OS (medians 13.7 vs. 5.1 months, hazard ratio 0.43 [95% CI, 0.23-0.77], P = 0.004) as compared with those whose DLBCL had C-MYC and BCL-2 overexpression. Among patients who had normal expression levels of either C-MYC or BCL-2 and baseline hemoglobin levels ≥ 10g/dL, ORR was 51.5% (n = 47), with median OS of 15.5 months and median PFS of 4.6 months. Similar rates of adverse events were noted in all subgroups. Overall, single agent oral selinexor showed strong responses in patients with limited treatment alternatives regardless of germinal center B-cell type or disease origin.
YR 2021
FD 2021-07-22
LK http://hdl.handle.net/10668/22107
UL http://hdl.handle.net/10668/22107
LA en
DS RISalud
RD Aug 1, 2025